Cocrystal Pharma, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Cocrystal Pharma announced last subject dosed in Phase 1b randomized, double-blind, placebo-controlled challenge study of CDI-988 for norovirus prevention/treatment at Emory University. No serious adverse events reported; primary endpoint is efficacy in reducing clinical symptoms; preliminary results expected late 2026 or early 2027. CDI-988 previously showed safety up to 1200 mg dose in Phase 1 Australia trial.
Why this rating
Clinical milestone de-risks lead asset for tiny $11.6M company; Phase 1b completion rare for stage; efficacy data pending but safety/tolerability established. Norovirus market substantial ($60B/year globally) but high uncertainty remains on efficacy and path to approval.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.